6 results about "Materia medica" patented technology

The present invention relates to a use of a compound represented by formula (I) and a pharmaceutically acceptable salt thereof in the field of pharmaceutics, and in particular an application thereof in the preparation of a drug for treating pneumonia.

The application belongs to the technical field of medicine, and discloses application of oxeladin in preparation of a medicine for preventing or treating perioperative hypothermia. The dose of the medicine ranges from 1 to 3 mg. The medicine is applied to perioperative hypothermia caused by general anesthesia. The general anesthesia includes sevoflurane and esketamine. The medicine further comprises a pharmaceutically acceptable carrier and / or excipient. It is found in the previous application that the incidence of hypothermia and chills after general anesthesia is significantly reduced in the oxeladin administration group compared with the blank control group, and the further verification is carried out through animal experiments. The achievement of the application provides an effective prevention and treatment scheme for improving perioperative hypothermia and chills in clinic.

1. Name of the designed product: playing cards (Materia Medica). 2. Use of the designed product: the designed product is used for entertainment, souvenirs. 3. Design points of the designed product: the pattern. 4. Picture or photo best indicating the design points: front view of component 1. 5. Rear views of components 1 to 54 are the same, and rear views of components 2 to 54 are omitted; components 1 to 54 are flat printed matter, and the remaining views are omitted.

The present application relates to the field of medicinal chemistry and pharmacotherapy, in particular to a phenylpiperazine compound or a pharmaceutically acceptable salt thereof, a preparation method and use thereof in the preparation of analgesic drugs or drugs for treating pain, wherein the phenylpiperazine compound or the pharmaceutically acceptable salt thereof has the following structure: the phenylpiperazine compound has obvious inhibitory activity on TRPV1, can obviously inhibit the pain response, and has no side effect of body temperature rise.

This invention discloses the application of lupinone in the preparation of drugs for treating psoriasis, belonging to the field of pharmaceutical technology. In this invention, lupinone is used to treat psoriasis by regulating CD4 levels in psoriasis patients. + FoxP3 + The number of Tregs, regulatory T lymphocytes, reduces the expression of CD3-positive cells and the level of inflammatory factors in the skin lesions of psoriasis patients, thereby regulating the immune response of psoriasis patients and thus achieving the treatment of psoriasis. Specifically, it can reduce the severity of psoriasis, improve the degree of erythema, scaling and infiltration of skin lesions, significantly reduce the PASI (Psoriasis Area and Severity Index) score of skin lesions, reduce the thickness of the epidermis at the skin lesion site and inhibit epidermal proliferation, improve hyperkeratosis and parakeratosis, and improve acanthosis.

The invention discloses application of dihydroresveratrol in preparation of a medicine for treating depression, and belongs to the technical field of biological medicine. DHR or a pharmaceutically acceptable solvate thereof is taken as an active ingredient and can also be combined with fluoxetine for use, the use dosage of DHR is 1-100mg / kg, the use dosage of fluoxetine is 1-100mg / kg, and the dosage form is selected from at least one of tablets, capsules, granules, dripping pills, suspensions, syrups, enteric preparations, emulsion suspensions and injections. The invention also provides a pharmaceutical composition for treating depression. The pharmaceutical composition comprises DHR or a pharmaceutically acceptable solvate thereof. A chronic unpredictable mild stress mouse model verifies the effect of DHR in regulating neuroinflammation, oxidative stress, neuronal growth and the like, verifies that the effect of DHR in treating depression is better than that of fluoxetine used clinically, and has important clinical application value.